After a very long, very public [1] selection process, GlaxoSmithKline has appointed Andrew Witty (photo [2]), now president of the company's European pharma division, to succeed Jean-Pierre Garnier as CEO in May. Analysts said he'd been able to grow sales significantly in Europe despite pricing pressures--an ability that may help him in the U.S. as well. Report [3]
Links:
[1] http://www.fiercebiotech.com/story/gsk-public-race-top-spot/2007-09-24
[2] http://www.fiercebiotech.com/story/glaxosmithkline-ceo-andrew-witty/2007-10-08
[3] http://www.fiercepharma.com/story/gsk-taps-witty-next-ceo/2007-10-08